Listed

Burning Rock Biotech Ltd: Form 20-F for the period ended Dec 31, 2023

Filed with the SEC on Apr 29, 2024 and accepted by EDGAR at Apr 29, 2024, 06:17 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2023-01-01 to 2023-12-31$75.7mus-gaap:Revenues
Cost of revenue12 months2023-01-01 to 2023-12-31$24.5mus-gaap:CostOfRevenue
Gross profit12 months2023-01-01 to 2023-12-31$51.2mus-gaap:GrossProfit
Research and development12 months2023-01-01 to 2023-12-31$48.9mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2023-01-01 to 2023-12-31−$94.3mus-gaap:OperatingIncomeLoss
Income tax12 months2023-01-01 to 2023-12-31$336.0kus-gaap:IncomeTaxExpenseBenefit
Net income12 months2023-01-01 to 2023-12-31−$92.1mus-gaap:NetIncomeLoss
Operating cash flow12 months2023-01-01 to 2023-12-31−$36.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2023-01-01 to 2023-12-31$1.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-12-31$86.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-12-31$124.5mus-gaap:AssetsCurrent
Total assetsAt period end2023-12-31$146.5mus-gaap:Assets
Current liabilitiesAt period end2023-12-31$37.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-12-31$38.3mus-gaap:Liabilities
Shareholders' equityAt period end2023-12-31$108.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-24-119655. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.